Impact of tumor location on oncological and perioperative outcomes after robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma
PLOS One · 2026
DOI: 10.1371/journal.pone.0341638 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Mahmoud Farzat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig University of Giessen, Giessen, Germany. Hauptthemen laut MEDLINE: Nephroureterectomy, Robotic Surgical Procedures, Ureteral Neoplasms, Carcinoma, Transitional Cell. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective to investigate the effect of tumor location on oncological outcomes in patients receiving robot-assisted radical nephroureterectomy (RANU) for upper urinary tract carcinoma (UTUC).
Methods
A retrospective single-center cohort study of 54 patients with UTUC who underwent RANU by a single surgeon between July 2019 and July 2025, without neoadjuvant chemotherapy or previous or simultaneous cystectomy, were included. Patients were divided into two groups based on tumor location: 18 patients (33%) with ureteral tumors (Group 1) and 36 patients (67%) with renal pelvis tumors (Group 2). Demographics, perioperative data, and pathological results were analyzed. The primary endpoints Cancer-specific survival (CSS) and overall survival (OS) were estimated using Kaplan–Meier and univariable log-rank test.
Results
Console time, blood transfusion, complications, and readmission were comparable in both groups. Group 1 experienced longer hospital stays (8 days vs. 6.5 days, p = 0.03). 48% of patients had ≥ pT2 disease, with a similar T-stage distribution across groups. Of 26 candidates for adjuvant therapy, 10 received chemotherapy with gemcitabine/cisplatin, 2 received nivolumab, and one patient received enfortumab vedotin with pembrolizumab. During a median 26.5-month follow-up, six patients developed bladder recurrence, (median 9 months) after RANU (p = 0.10), and four developed distant metastases (median 4 months) (p = 0.72), resulting in a disease-free survival of 81% (p = 0.08)Cancer-specific survival was 94%, overall survival 89%, with no significant group differences (p = 0.24 and 0.49).
Conclusion
In our series, we observed that tumor location does not impact postoperative and oncological outcomes after RANU for UTUC, regardless of adjuvant therapy. However, further studies are needed to explore this proposed hypothesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig University of Giessen, Giessen, Germany.
- Department of Urology and Robotic Urology, Diakonie Klinikum Siegen, Siegen, Germany.
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Mahmoud Farzat
Zitieren
APA
Farzat, M., Altaie, I., Leyh-Bannurah, S. R., Kachanov, M., & Wagenlehner, F. M. (2026). Impact of tumor location on oncological and perioperative outcomes after robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0341638
Vancouver
Farzat M, Altaie I, Leyh-Bannurah SR, Kachanov M, Wagenlehner FM. Impact of tumor location on oncological and perioperative outcomes after robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma. PLOS One. 2026. doi:10.1371/journal.pone.0341638
BibTeX
@article{Farzat2026,
author = {Farzat, Mahmoud and Altaie, Ibrahim and Leyh-Bannurah, Sami-Ramzi and Kachanov, Mykyta and Wagenlehner, Florian M},
title = {Impact of tumor location on oncological and perioperative outcomes after robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0341638}
}
EUVIMED